Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials

Table 3

Ongoing progenitor cell-therapy in orthopaedic patients.

Indications	Sponsors	Phase	Age range	Study type	Intervention	Source	Route of administration	Clinical TrialID no.	Status
Bone defects	Emory University	II + III	11 years and older	Interventional	Trinity MPC & DBM	Commercial	Direct filling of bone defects with progenitor cells	NCT00851162	Not yet recruiting
Fracture nonunion	Aastrom Biosciences	I + II	18 years and older	Interventional	Fracture surgery + Cultured BM tissue	Autologous BM	Direct admiministration to site of fracture	NCT00424567	Completed
Dital tibial fracture	Hadassah Medical Organization	I + II	18–65 years	Interventional	Autologous “MSC” implantation	Autologous BM	Cells loaded onto a carrier and implanted locally at the fracture site	NCT00250302	Recruiting
Knee Cartilage defects osteoarthritis	Royan Institute	I	45–60 years	Interventional	Autologous “MSC” implantation	Autologous BM	Cells loaded on collagen I scaffold are implanted locally to the cartilage defect site	NCT00850187	Recruiting
Osteochondral defects	Cairo University	I + II	15–55 years	Interventional	Autologous “MSC” implantation	Autologous BM	Cell pellets will be implanted into osteochondral defect via open surgery or arthroscopically	NCT00891501	Recruiting
Cartilage Defects	Ullevaal University Hospital	I	18–50	Interventional	Autologous “MSC” implantation versus chondrocyte implantation	Commercial	Cells loaded on commercially available scaffolds and implanted locally at the cartilage defect site	NCT00885729	Recruiting
Meniscectomy	Osiris Therapeutics	I + II	18–60	Interventional	Chondrogen versus placebo	Chondrogen (commercial)	Intra-articular injection	NCT00702741	Ongoing but not recruiting
Chondral defect	Medipost Co Ltd.	III	18 years and older	Interventional	Cell therapy versus microfracture	UCB	Culture expanded cells mix semisolid polymer will be implanted locally at the site of chondral defect	NCT01041001	Recruiting
Osteonecrosis of the femoral head	Fuzhou General Hospital	I + II	12–60 years old	Interventional	Autologous MSC	N/A	Direct cellular infusion through tubes inserted into MFCA, LFCA, and OA	NCT00813267	Not yet recruiting
OI Type I + II	Children's Hospital of Philadelphia	I	≤19 years	Interventional	Infusion Haploidentical MSCs in patients with history of VM transplant versus No history of transplant	Donor BM	Repeat infusion of MSCs in sub	NCT01061099	Recruiting
Osteodysplasia	St. Jude Children's Research Hospital	I	N/A	Interventional	Infusion of ex vivo expanded gene marked BMSC following allogenic BM transplantation	Donor BM	IV Infusion	NCT00186914	Completed

MPC: mesenchymal progenitor cells, DBM: demeneralized bone matrix, BM: bone marrow, MSC: mesenchymal stem cell, MFCA: medial femoral circumflex artery, LFCA: lateral femoral circumflex artery, OA: obturator artery, IV: intravenous, UCB: umlical cord blood, N/A: not available.